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Editorial
Renal Sympathetic Denervation:  
Using an Old Tool for a New Job?
Jeff S. Healey
A rterial hypertension remains an important cause of morbidity and mortality, and is one of the main causes of stroke, heart failure, and atrial fibril-
lation.1 Although drug therapy reduces blood pressure 
(BP),2 many patients do not achieve adequate control 
of BP levels, due to side effects of medication, poor 
adherence to treatment, and the presence of refractory 
hypertension.3 For these reasons, there has been great 
interest in recent reports suggesting that catheter-based 
renal sympathetic-nerve ablation through the renal artery 
can significantly reduce BP.4,5
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In this issue of the Revista Brasileira de Cardiolo-
gia Invasiva (Brazilian Journal of Invasive Cardiology), 
Staico et al.6 publish the results of an ex vivo study, 
in which 18 ablations were performed in six porcine 
renal arteries, using three different radiofrequency ab-
lation catheters designed for intracardiac procedures. 
The authors demonstrated that with adequate power, 
duration, and flow, it is possible to perform effective 
ablation of renal nerves from the renal artery lumen. 
The irrigated-tip catheter, produced deeper lesions, but 
the solid-tip, 4 mm/7F catheter, was also effective in 
nervous tissue ablation. The use of an ex vivo model 
is a logical first step; however, in vivo studies with 
this technique are needed if we are to have clear 
understanding of its clinical efficacy and potential for 
collateral damage.
Their article not only provides useful data, but also 
raises important issues and highlights the need for more 
research in the field of renal denervation therapy. The 
experiment by Staico was inspired by the lack of ac-
cess, in Brazil, to equipment specifically designed for 
renal sympathetic ablation. The adaptation of commonly 
available cardiac ablation equipment makes sense from 
the intuitive point of view; however, the clearly off-
label indication of these devices has yet to be studied. 
In the United States, the manual of catheters used for 
radiofrequency ablation usually indicates that they 
are designed for intracardiac use, and in the case of 
irrigated-tip catheters, it often specifies the types of 
arrhythmia they should be used for.7
Although renal denervation is a promising treat-
ment for a very common problem, this therapeutic 
strategy is still in its infancy. Long-term randomized 
trials are necessary to confirm the safety and efficacy 
of this technique, and its impact on clinically impor-
tant outcomes, such as stroke and heart failure. At the 
current stage, we must be cautious in our enthusiasm 
and particularly prudent regarding the performance 
of procedures using different approaches from those 
demonstrated in previously published studies.4,5 The 
use of intracardiac ablation catheters to perform renal 
ablation is a practical potential solution in regions 
where dedicated catheters are not available, and it is 
a potentially cost-effective approach in hypertensive 
patients submitted to catheter ablation, typically for 
atrial fibrillation. However, it represents a different 
technique, which should be submitted to an evalua-
tion similar to that of renal denervation with the use 
of specifically-designed catheters.4,5 The authors of 
this study should be congratulated for their careful 
approach in conducting the experiment.
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